GlassScriptPhysician profile
Samaneh Dowlatshahi
NPI 1760737068
$1,477.27
in general payments reported to CMS, 2019-2025
18 companies · $19.54 in 2025
The $19.54 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.10 · 2020: $179 · 2021: $102 · 2022: $80.03 · 2023: $526 · 2024: $489 · 2025: $19.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,034.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $414.55 | 2024 | Ilet Bionic Pancreas |
| Xeris Pharmaceuticals, INC. | $272.83 | 2022-2023 | Recorlev |
| Amgen INC. | $251.02 | 2020-2025 | Tepezza |
| Dexcom, INC. | $157.85 | 2021-2023 | Dexcom G6 Transmitter |
| Insulet Corporation | $70.84 | 2023 | Omnipod |
| Abbott Laboratories | $53.41 | 2020-2023 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.28 | 2019-2021 | |
| Lilly USA, LLC | $31.79 | 2021-2023 | Mounjaro, Trulicity |
| Novo Nordisk INC | $31.20 | 2019-2021 | |
| Ultragenyx Pharmaceutical INC. | $19.92 | 2023 | Crysvita |
| Ascensia Diabetes Care US INC. | $19.90 | 2020 | |
| Cequr Corporation | $18.66 | 2022-2023 | Cequr Simplicity |
| Corcept Therapeutics | $17.39 | 2023 | Korlym |
| Radius Health, INC. | $17.32 | 2023 | Tymlos |
| Janssen Pharmaceuticals, INC | $14.96 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $13.56 | 2021 | |
| Ibsa Pharma INC. | $12.26 | 2020 | |
| Amneal Pharmaceuticals LLC | $11.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samaneh Dowlatshahi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.